Skip to main content

Peripheral arterial disease

30-09-2021 | EASD 2021 | Conference coverage | News

AF, PAD, diabetes prevention data reported from DAPA-CKD

The latest DAPA-CKD data show the large absolute benefits of dapagliflozin treatment in people with peripheral artery disease or atrial fibrillation, and that the medication may reduce the risk for type 2 diabetes in people with initial prediabetes.

01-09-2021 | ESC 2021 | Conference coverage | News

‘Exceedingly high’ vascular event risk with type 2 diabetes plus PAD

The risk for major adverse cardiovascular events in people with type 2 diabetes plus peripheral artery disease exceeds even that of those with coronary artery disease, researchers report.

Chalkboard image of patient with heart failure

24-06-2020 | Heart failure | Highlight | News

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

20-03-2019 | Peripheral arterial disease | News

DECLARE-TIMI 58 outcomes consistent in people with peripheral artery disease

Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.